Company intelligence / Profile preview

Ionetix

San Francisco, California, United Statesionetix.com ↗

Ownership: Private
Development stage: Other

Overview

Ionetix has established a nationwide network of compact cyclotrons to provide on-demand production of N13 Ammonia for advanced cardiac PET imaging. The company is also scaling up commercial-stage production of key therapeutic alpha-emitting isotopes such as Actinium‑225, supporting the development and future commercialization of targeted alpha therapies in oncology. Recent milestones include successful high-purity Ac‑225 production at their dedicated Michigan facility.

Therapeutic areas: OncologyCardiovascular
Modalities: RadiopharmaceuticalTargeted alpha therapyDevice (cyclotron technology)
Industry: Medical Imaging

Partnerships

Not explicitly listed; partners with health systems/hospitals/nuclear medicine providers to deploy its cyclotrons and distribute radiopharmaceuticals nationwide

Beyond the preview

Go deeper on Ionetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ionetix.